L3VLUP
ProSign in

CGEN · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CGENAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CGEN
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterCGENAMGN
Q3 20203 holders, $301m16 holders, $16.3bn
Q4 20205 holders, $222m19 holders, $14.0bn
Q1 20215 holders, $137m16 holders, $14.5bn
Q2 20213 holders, $107m23 holders, $13.8bn
Q3 20213 holders, $64m24 holders, $11.6bn
Q4 20213 holders, $44m21 holders, $10.4bn
Q1 20222 holders, $36m23 holders, $9.9bn
Q2 20222 holders, $21m28 holders, $9.7bn
Q3 20222 holders, $2.1m21 holders, $7.9bn
Q4 20221 holders, $1.7m24 holders, $9.3bn
Q1 2023none listed holders, n.a.22 holders, $8.4bn
Q2 2023none listed holders, n.a.26 holders, $7.4bn
Q3 2023none listed holders, n.a.26 holders, $8.7bn
Q4 2023none listed holders, n.a.24 holders, $8.4bn
Q1 20241 holders, $2.7m25 holders, $6.7bn
Q2 20241 holders, $1.9m20 holders, $8.0bn
Q3 20241 holders, $2.0m21 holders, $8.8bn
Q4 2024none listed holders, n.a.20 holders, $8.2bn
Q1 20251 holders, $1.3m25 holders, $12.0bn
Q2 20251 holders, $1.8m20 holders, $10.2bn
Q3 2025none listed holders, n.a.17 holders, $10.4bn
Q4 2025none listed holders, n.a.19 holders, $18.0bn
Q1 20261 holders, $2.2m15 holders, $21.4bn
Q2 20261 holders, $1.7m23 holders, $24.9bn
CGEN

Compugen LTD

Holders
0
Reported value
$0
Buyers
4
Sellers
6

Breadth -2 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
19
Reported value
$18.0bn
Buyers
13
Sellers
22

Breadth -9 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 19 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only CGEN (0)

None.

Only AMGN (19)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Capital Research Global Investors, Capital World Investors, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →